Patients be informed of risks in self-administration: CDSCO Panel tells Takeda Biopharm on Agalsidase Alfa Susmita Roy11 Nov 2024 6:00 PM ISTNew Delhi: In line with the proposal presented by Takeda Biopharmaceuticals for an update in the package insert regarding home infusion for Agalsidase...
Submit Separate Retrospective, Prospective Study data of subjects: CDSCO Panel Tells Takeda on Velaglucerase alfa study Dr. Divya Colin15 July 2024 6:00 PM ISTNew Delhi: Regarding the post-marketing surveillance study of the drug major Takeda Pharmaceutical's Velaglucerase alfa injection, the Subject Expert...
Early initiation of ERT in Fabry disease can eliminate major organ damage and yield enhanced long-term benefits: Case Study Medha Baranwal28 Feb 2024 2:15 AM ISTChina: A recent article published in BMC Nephrology reports a case study of enzyme replacement therapy for Fabry disease (FD) presenting with...
Sanofi Gets CDSCO Panel Nod To Market Avalglucosidase Alfa Powder for Pompe Disease Dr. Divya Colin28 Jan 2023 6:00 PM ISTNew Delhi: Granting a local Phase III and Phase IV clinical trial waiver, the Subject Expert Committee (SEC) functional under the Central Drug...
Why suggestion to have CSR account in govt hospitals not followed: HC asks Centre, Delhi govt Medical Dialogues Bureau14 March 2019 4:16 PM ISTNew Delhi: The Delhi High Court on Wednesday asked the Centre and the AAP government why they have not followed its suggestion to have a separate...
Implement national policy on rare diseases: HC tells Centre savita thakur thakur23 Aug 2017 9:40 AM ISTNew Delhi:Â The Delhi High Court has asked the Centre to take urgent steps to make the National Policy for Treatment of Rare Diseases functional at the...
